Abstract 【Objective】To investigate the effects of Tirofiban combined with adenosine on microcirculation and cardiac function in patients with coronary heart disease after percutaneous coronary intervention (PCI). 【Objective】A total of 120 patients with coronary heart disease who underwent PCI in our hospital from January 2020 to May 2022 were selected and divided into observation group and control group by random number table, with 60 cases in each group. The control group was given tirofiban before surgery, the observation group was given Tirofiban combined with adenosine before surgery. The serum levels of cardiac troponin I (cTnI) and creatine kinase isoenzyme (CK-MB) were compared between the two groups before and after operation. The indexes of myocardial microcirculation immediately after operation[thrombolysis in myocardial infarction(TIMI) blood flow grading and correcting TIMI frame count (CTFC)] were compared between the two groups. The indexes of cardiac function before and after operation [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)]were compared between the two groups. The incidence of major adverse cardiovascular events(MACE) was also compared between the two groups. 【Results】Before operation, there was no significant difference in serum cTnI and CK-MB levels between 2 groups (P>0.05). After operation, serum cTnI and CK-MB levels in 2 groups were lower than before operation, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). There was no significant difference in immediate TIMI blood flow classification between the two groups (P>0.05). The CTFC immediately after operation in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). The level of LVEF after operation was higher than before operation, and the level of LVESD and LVEDD were lower than before operation, the difference was statistically significant (P<0.05). The LVEF level in the observation group was higher than that in the control group, and the LVESD and LVEDD levels were lower than that in the control group, with statistical significance (P<0.05). The incidence of MACE in the observation group was 1.67% (1/60), significantly lower than that in the control group 15.00% (9/60), and the difference was statistically significant (P<0.05). 【Conclusion】Tirofiban combined with adenosine can effectively improve myocardial microcirculation and cardiac function in patients with coronary heart disease before PCI.
LI Nini,LI Xinguo. Effect of Tirofiban Combined with Adenosine on Microcirculation and Cardiac Function in Patients with Coronary Heart Disease after PCI[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(1): 71-74.
[1] THUIJS D , PIETER K A , SERRUYS P W , et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial[J].Lancet,2020, 394(206):1325-1334. [2] VALOORAN G J , SUBBIAH M , IDHREES M , et al. Percutaneous catheter-based repeat revascularization in patients with previous PCI or CABG: a comprehensive review of the evidence[J].Vessel Plus,2022, 6(1):142-145. [3] 崔维佳,谢金洲,罗炼,等.高强度间歇训练心脏康复对冠心病患者PCI术后心脏功能及应激因子的影响[J].现代生物医学进展,2021,21(17):3346-3349. [4] 李志龙, 王万虹, 丁浩,等. 经血栓抽吸导管注射替罗非班和三磷酸腺苷对重度血栓负荷急性前壁心肌梗死患者急诊PCI效果的影响[J].中国循证心血管医学杂志, 2019, 11(2):56-61. [5] 潘信伟,陈曙霞,陆洁如,等.冠心病诊断标准的探讨[J].临床心血管病杂志,1986,6(2):136-139. [6] HANNA-RIIKKA L, KLAS W, ARTO P, et al. Outcomes after coronary artery bypass grafting and percutaneous coronary intervention in diabetic and non-diabetic patients[J].Eur Heart J Qual Care Clin Outcomes,2021,8(6):692-700. [7] WANG P, ZHAO X, YUAN Q M, et al. Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study[J].Chin Med J (Engl),2022, 135(1):116-118. [8] 张健发,刘婕,黄定. PCI术中联合使用腺苷与盐酸替罗非班对老年急性ST段高型心肌梗死心肌微循环及心功能的影响[J].中国老年学杂志,2014,34(12):3231-3233. [9] 刘茂兰.替罗非班联合比索洛尔对冠心病介入治疗的疗效及对心功能的影响[J].心血管康复医学杂志,2020,29(3):369-373. [10] 戴艺,代世地,向涛,等.冠心病PCI术后应用阿司匹林加小剂量替罗非班对其血栓形成的预防效果及心功能的影响研究[J].临床和实验医学杂志,2021,20(2):154-157. [11] 刘杰,刘蕾,金超岭,等. 三磷腺苷负荷脑血流灌注显像对后循环缺血病变的评估价值[J].中日友好医院学报,2021,35(5):265-267. [12] 陈涛,周致远,袁明,等.腺苷联合替罗非班对老年急性ST段抬高型心肌梗死PCI术后再灌注损伤及心功能的保护作用研究[J].中西医结合心脑血管病杂志,2019,17(18):2803-2806. [13] 佟子川,李强,陈明,等. 冠状动脉内联合应用腺苷和替罗非班与单独应用替罗非班在直接冠状动脉介入治疗中的疗效比较[J].中华心血管病杂志,2013,41(10):839-844. [14] 李世权,李书辉,董曜伟. 替罗非班联合介入治疗对急性心肌梗死患者cTnI、BNP及心功能的影响[J].右江医学,2019,47(1):27-30. [15] 朱小芬,陈波.PCI围术期联合腺苷与盐酸替罗非班对老年STEMI患者心肌微循环及心功能的影响[J].中国老年学杂志,2015,48(15):4219-4221.
2025, Vol. 42 
